Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Artículo Open Access |
| Veröffentlicht: |
Wiley
2025
|
| Schlagworte: | |
| Online-Zugang: | https://onlinelibrary.wiley.com/doi/10.1111/ctr.70187 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Inhaltsangabe:
- Use of Letermovir as Secondary Prophylaxis in Cytomegalovirus Resistant Pediatric Heart Transplant Recipients John‐Anthony Coppola Debbie‐Ann Shirley Emily Martin Varvara Probst Dipankar Gupta Clinical Transplantation ABSTRACT Introduction Cytomegalovirus (CMV) is a prevalent DNA virus that is a well‐recognized cause of significant complications in post‐transplant recipients. Emergence of CMV resistance to standard antiviral agents poses a substantial challenge for appropriate management post‐transplantation. Currently, there are no pediatric heart transplant data on the use of novel agents such as letermovir for the management of resistant CMV infection. Methods We present our experience using letermovir in the management of three pediatric heart transplant recipients with CMV infection who developed resistance to standard therapy. Informed consent was not required. Results Letermovir was successfully used for secondary prophylaxis in three patients, all with ganciclovir resistant CMV infection due to UL97 mutations, with no evidence of CMV breakthrough infection and no significant side effects observed. Conclusion In our experience, letermovir was well tolerated and effective in the management of resistant CMV in pediatric heart transplant recipients. 10.1111/ctr.70187 http://onlinelibrary.wiley.com/termsAndConditions#vor